SUNDAY, SEPTEMBER 25, 2016

NAIAID awards three contracts to AIDS researchers for SVEU efforts.

Three Simian Vaccine Evaluation Unit contracts were given on Monday by the National Institute for Allergy and Infectious Diseases to aid the research of non-human primate immunogenicity and pilot studies of new antivirals and vaccines.

The SVEU awards will fund non-human primate resources to support preclinical evaluation of AIDS vaccines. The recipients will use state-of-the-art technologies to evaluate promising candidates for an AIDS vaccine.

AIDS is a serious disease caused by the HIV virus. The virus attacks the human immune system and can trick white blood cells into believing the virus is a helpful organism.

HIV is spread by unprotected sexual intercourse, contaminated blood transfusions, hypodermic needles and from mother to child during birth. HIV originally came from west-central Africa in the mid twentieth century.

AIDS does not have a vaccine or cure, but can be contained with the use of numerous drugs. These drugs are a temporary, and expensive, solution to the AIDS problem.

Advance BioScience Laboratories, Inc., Bioqual, Inc., and Tulane University each received a base award of $100,000 and will be unable to receive more than $80,426,435 from their SVEU contracts.

The contract awards will help boost the labs and facilities of the three recipients.